Adults 21 to 65, any sex, with Smoking, Cigarette. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Attention: Latency (Time Until First Fixation) for ImagePrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
2612
± 308
Condition B (Well-known Harms)
978
± 313
Attention: Latency (Time Until First Fixation) for TextPrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
1001
± 214
Condition B (Well-known Harms)
798
± 218
Attention: Latency Duration (Time of Fixation) for ImagePrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
160
± 11
Condition B (Well-known Harms)
183
± 13
Attention: Latency Duration (Time of Fixation) for TextPrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
150
± 9
Condition B (Well-known Harms)
165
± 9
Attention: Total Fixation Time for ImagePrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
3532
± 524
Condition B (Well-known Harms)
7887
± 532
Attention: Total Fixation Time for TextPrimary· Day 1
We defined areas of interest (AOIs) encompassing the image and text portions of each PWL. For each AOI, we examined attention measures of latency (time until the first fixation in the AOI; i.e., how quickly attention is drawn to the AOI), latency duration (length of the first fixation; i.e., how long the AOI is initially viewed), and total fixation time (sum of all fixations in the AOI; i.e., overall viewing allocation, accounting for viewing the same AOI multiple times). Analyses examined the mean of each outcome across the four PWLs within each condition.
Group
Value
95% CI
Condition A (Lesser-known Harms)
4889
± 436
Condition B (Well-known Harms)
3643
± 443
Recall: Participants Ability to Recall Condition ImagePrimary· Day 1
Participants will view 11 warning label images and would be required to identify the warning label images they saw during their eye tracking portion of the session. This outcome measure (Recall -Image) was assessed in a percentage unit of measure. The percentages are not whole numbers for these items because it's the mean % correct for the condition, or the average percent correct across the four images for the group. The results in the Outcome Measure Data table demonstrate the percentage of participants who correctly identified the images from their condition (4 of the 11 images presented to
Group
Value
95% CI
Condition A (Lesser-known Harms)
98.6
± 1.0
Condition B (Well-known Harms)
95.7
± 1.6
Recall: Participants Ability to Recall Condition TextPrimary· Day 1
Participants will view 11 warning label text statements and would be required to identify the warning label text statements they saw during their eye tracking portion of the session. This outcome measure (Recall -Text) was assessed in a percentage unit of measure. The percentages are not whole numbers for these items because it's the mean % correct for the condition, or the average percent correct across the four images for the group. The results in the Outcome Measure Data table demonstrate the percentage of participants who correctly identified the text statements from their condition (4 of
Group
Value
95% CI
Condition A (Lesser-known Harms)
82.9
± 3.9
Condition B (Well-known Harms)
86.5
± 3.1
Knowledge of Smoking HarmsPrimary· Day 1
All participants will select harms caused by tobacco from a list of health issues and diseases, before as well as after viewing the warning labels on the screen. Pre and post warning label exposure knowledge of smoking harms were assessed by using an exploratory scale that asked participants if cigarette smoking caused a list of 18 health conditions with a 5-point response scale, (1=definitely yes 2= probably yes, 3 = might or might not, 4 = probably not, 5 = definitely not).
Head and Neck Cancer
Group
Value
95% CI
Condition A (Lesser-known Harms)
1.4
± 0.2
Condition B (Well-known Harms)
3.0
± 0.2
Hearing Loss
Group
Value
95% CI
Condition A (Lesser-known Harms)
3.3
± 0.2
Condition B (Well-known Harms)
3.9
± 0.2
Lung Disease
Group
Value
95% CI
Condition A (Lesser-known Harms)
1.3
± 0.1
Condition B (Well-known Harms)
1.3
± 0.1
Vertigo
Group
Value
95% CI
Condition A (Lesser-known Harms)
3.0
± 0.2
Condition B (Well-known Harms)
3.3
± 0.2
Cataracts
Group
Value
95% CI
Condition A (Lesser-known Harms)
1.8
± 0.2
Condition B (Well-known Harms)
3.4
± 0.2
Depression
Group
Value
95% CI
Condition A (Lesser-known Harms)
2.7
± 0.2
Condition B (Well-known Harms)
3.1
± 0.2
Erectile Dysfunction
Group
Value
95% CI
Condition A (Lesser-known Harms)
3.2
± 0.2
Condition B (Well-known Harms)
3.3
± 0.2
Bladder Cancer
Group
Value
95% CI
Condition A (Lesser-known Harms)
1.9
± 0.2
Condition B (Well-known Harms)
2.8
± 0.2
Sponsor's own description
The purpose of this study is to examine the effect of cigarette pictorial warning label content (lesser-known vs well-known risks) on visual engagement, recall, and knowledge of tobacco use harms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy
· NA
· recruiting
NCT06945120 — ACT Lung Health Intervention: Phase Two
· NA
· recruiting
NCT06693700 — A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
· NA
· recruiting
NCT06535867 — The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorde
· recruiting
NCT05660525 — Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
· NA
· recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
· Phase 1
· not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
· Phase 2
· not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
· NA
· not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery
· NA
· recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 22 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04936724.